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counted at 5% per year. Deterministic and probabilistic sensitivity analyses (PSA) were 
performed to test the model robustness. RESULTS: Using clinical results of patients 
previously treated with a calcium-based binder, for the ITT population, the ICERs 
were $24,724/QALY, $15,053/LYS and $6,700/additional success (i.e., SP goal 
achievement), respectively. For patients who completed the randomized controlled 
trial, the ICERs of LC compared with SH were $15,285/QALY, $9,337/LYS and 
$8,265/additional success respectively. The PSAs indicated a 61.9% and 85.8% prob-
ability of LC being cost-effective at the $50,000/QALY threshold, for the ITT popula-
tion and completer populations, respectively. Sensitivity analyses support the 
robustness of the model results. CONCLUSIONS: LC is a cost-effective strategy 
compared to SH in ESRD patients previously treated with calcium-based binders.
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OBJECTIVES: The calcineurin inhibitor (CNI) based regimens have improved short-
term patient and graft survival. However, the nephrotoxicity of CNI has limited the 
long-term improvement of outcomes. Recently, sirolimus, a novel class of immunosup-
pressant, got an approval in Korea. In this report, the cost-effectiveness of sirolimus 
based regimen compared with CNI based regimens was evaluated especially in the 
lower immunological risk renal transplant patients under Korea health care system. 
METHODS: A Markov model was developed to simulate costs and outcomes of a 
renal transplant recipient for 20 years with 5% discount rate in the societal perspec-
tive. Health states were deﬁ ned as patient with graft survival, patient with graft failure, 
patient with regraft survival, patient with regraft failure and patient death. Quality 
adjusted life-years (QALYs) were taken as effectiveness parameter. Efﬁ cacy data were 
obtained from systematic review of immunosuppressive regimens in lower immuno-
logical risk renal transplant recipients. And the additional beneﬁ ts of mTOR inhibitor 
(including sirolimus), reduced nephrotoxicity and lower relative risk to the incidence 
of malignancy, were reﬂ ected in the model. Utility weights were obtained from pub-
lished literature. Costs were calculated by the Korean public institutional data and 
clinical expert opinions. Sensitivity analyses were performed on crucial parameters. 
RESULTS: Sirolimus based regimen costs KRW 130,067,696 for the 8.94QALYs for 
20 years treatment duration, whereas KRW 140,185,240 for 8.67 QALYs for tacro-
limus based regimen, and KRW 131,136,664 for 8.56 QALYs for cyclosporine based 
regimen. Sirolimus based regimen was shown to be dominant over the others, as it 
was more efﬁ cacious in QALYs and less costly. The sensitivity analysis showed that 
the results were quite robust across most parameters. CONCLUSIONS: Sirolimus 
based regimen is expected to be superior in the clinical effectiveness and cost-saving 
in lower risk renal transplant recipients compared with the most frequently prescribed 
CNI regimens in Korea.
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OBJECTIVES: Diabetic nephropathy is a serious and common complication in dia-
betic patients; however the onset and the course can be favourably inﬂ uenced by 
appropriate therapy when detected early. Current recommendations include testing of 
creatinine based estimation of glomerular ﬁ ltration rate (eGFR) and for microalbu-
minuria. Due to substantial limitations of creatinine, cystatin C (cysC) has been 
proposed as alternative marker for early detection of (chronic kidney disease) CKD. 
METHODS: We developed a Cost-Utility Model to simulate the long-term conse-
quences and disease progression for diabetic patients using serum cysC instead of 
Creatinine for monitoring of kidney function. Markov modelling techniques were used 
to estimate incidence of complications and disease progression, and Monte Carlo 
simulation accounted for uncertainty. The model includes 11 health states to describe 
the disease progression and occurrence of adverse events. Probabilities were derived 
from clinical and epidemiological studies. The cohort deﬁ nition was adapted from the 
UKPDS study. Direct medical costs from published sources were used and expressed 
in 2009 Euro from the payer’s perspective. QALYs and total costs were projected over 
a life-time horizon and discounted at 5% p.a. RESULTS: Early detection of CKD with 
cysC leads to lifetime costs of c52,950 and 14.19 QALYs (c3,732 per QALY). Detec-
tion with Creatinine amounts to c64,912 and 12.82 QALYs (c5,063 per QALY). Cost 
saving amounts to c11,962 per patient and a QALY gain of 1.37; these arise due to 
slower disease progression and reduced complications. The cumulative incidence of 
complications was estimated to be lower for cysC than Creatinine (−15%). Early 
detection with cysC leads to a decreased number of patient-years (14%-points) spent 
in ESRD, due to a later onset. Probabilistic sensitivity analyses demonstrated the 
robustness of the model. CONCLUSIONS: The economic beneﬁ t of using cysC is 
substantial, due to reduction in complications and disease progression as well as lower 
long-term costs.
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OBJECTIVES: Major controversy exists regarding the optimal treatment strategy in 
Acute Kidney Injury (AKI). The purpose of this study was to assess the incremental 
cost-effectiveness of continuous (CRRT) versus intermittent renal replacement therapy 
(IRRT) and conservative (CONS) AKI treatment in Belgium. METHODS: An area 
under the curve model was used, whereby patients are simulated using time-to-event 
data (survival analysis), combined with daily direct medical costs. Data were derived 
from the multi-centre SHARF4 study in which the three treatment modalities for AKI 
were compared. a time horizon of 2 years, starting from the admission to the hospital, 
was considered. Utility data were obtained from SF-36 assessment at 2 years and from 
literature data on in-hospital utility. RESULTS: Analyses indicated that mortality 
rates, cost and length of stay differed signiﬁ cantly between treatment mode during 
hospitalization. The mortality rate and the cost per day during the post-discharge 
follow-up period showed no signiﬁ cant difference between the treatment modes. 
Utility values, which improved gradually after admission to the hospital, revealed no 
signiﬁ cant differences between the three treatment strategies. Conservative treatment 
was associated with a 2-year cost of c34,090 and 0.49 QALYs. The CRRT was the 
most expensive therapy with a cost of c51,664 leading to 0.52 QALYs. The cost and 
QALYs associated with IRRT were c43,711 and 0.46. The ICER of CRRT versus 
IRRT was c131,604/QALY, while the ICER of CRRT versus CONS amounted to 
c651,318/QALY. Additionally the conservative treatment dominated IRRT. Sensitiv-
ity analysis—tornado diagram—conﬁ rmed the robustness of the results. CONCLU-
SIONS: This study has indicated that the most expensive treatment (CRRT) associated 
with an incremental cost of approximately c7952 generates only a minor increase in 
QALYs of 0.06 compared to IRRT. Additionally the results revealed that IRRT was 
dominated by CONS. From a health economic perspective conservative therapy seems 
to be the preferred treatment strategy.
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OBJECTIVES: A probabilistic patient-level Markov model was developed to simulate 
lifetime clinical and economic outcomes of the cinacalcet treatment in secondary 
hyperparathyroidism (SHPT) patients. We present the adaptation of this model to ﬁ ve 
European countries: Italy, Spain, Portugal, Czech Republic and Switzerland. 
METHODS: In the simulation the treatment with cinacalcet inﬂ uences the trend in 
time of individual parathyroid hormone (PTH), serum calcium (Ca) and phosphorous 
(P) levels, based on the OPTIMA study. Published correlations between these levels, 
mortality and morbidity (CV events, fractures, and parathyroidectomies) were incor-
porated as well as local epidemiologic and cost data for dialysis, drugs and events 
management. Simulation horizon was patient lifetime; standard treatment (vitamin D 
sterols and phosphate binders) and cinacalcet plus standard treatment were compared. 
The effectiveness was measured as life expectancy (LE) and quality-adjusted life 
expectancy (QALE). Health Utility Indexes derived from literature and took into 
account dialysis, CV events and fractures. RESULTS: The simulated mean LE exten-
sion was 1.20 life-years (LY) in Italy, 1.1 LY in Spain, 1.18 LY in Portugal, 1.10 LY 
in Czech Republic and 1.40 LY in Switzerland. QALE increase was 0.89, 0.82, 0.89, 
0.80 and 1.01 quality-adjusted life-years (QALY) in the same countries, respectively. 
The lifetime average cost increase, calculated not taking into account the cost for 
dialysis, was c28,161 in Italy, c23,878 in Spain, c27,932 in Portugal, CZK 836,914 
(corresponding to c32,751) in Czech Republic and CHF 48,908 (c34,630) in Switzer-
land. The incremental cost-effectiveness ratio (ICER) was c23,473/LY and c31,616/
QALY in Italy, c21,789/LY and c29,270/QALY in Spain, c23,680/LY and c31,249/
QALY in Portugal, CZK 759,600/LY (approx. c29,726/LY) and CZK 1,042,643/
QALY (approx. c40,802/QALY) in Czech Republic and CHF 34,858/LY (approx. 
c24,682/LY) and CHF 48,310/QALY (approx. c34,207/QALY) in Switzerland. CON-
CLUSIONS: Cinacalcet treatment could be considered a cost-effective treatment of 
SHPT in all the countries analyzed. Results seem more homogeneous in the three 
southern countries.
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OBJECTIVES: Pharmacological interventions that are of beneﬁ t in non-dialysis popu-
lations have thus far been disappointing in dialysis patients. Since clinical trials are 
expensive and time-consuming, adjunct strategies are needed to support decision 
